ParaPRO announces first scabies drug to hit market in 30 years

Natroba is the only prescription scabies treatment that meets the new FDA's "Complete Cure" criteria.

ParaPRO, a speciality pharma company focusing on innovative anti-parasitic treatments announces Natroba™ (spinosad) as the first new drug for scabies to be approved by the FDA in over 30 years. Earlier this year, the company received the FDA green light approval of its supplemental new drug application for Natroba as a targeted topical treatment for scabies infestations in adult and paediatric patients four years of age and older. The drug, which is already on the market, having been approved for the topical treatment of head lice infestations since 2011, is said to be the only FDA-approved, targeted topical prescription therapy that meets the new FDA criteria for a "complete cure" in treating scabies infestations. The new criteria is defined as a drug being both clinical and confirmatory.

Scabies is a contagious skin disease caused by an infestation of the skin by a human itch mite. The disease occurs worldwide and causes symptoms such as intense itching and a pimple-like skin rash. “There are known limitations with existing scabicides, and for more than 30 years, practitioners have had to rely on the same active pharmaceutical ingredients to treat scabies," said Bill Culpepper III, president of ParaPRO. He added, "We are pleased to offer healthcare providers and their patients the first pharmacological advancement in scabies treatment in decades. Natroba is a targeted topical therapy that was shown to be highly effective and well-tolerated in the treatment of scabies following one application of the study drug."